Findings of an observational study of neuraminidase inhibitors highly sensitive to decision to exclude 1652 treated patients

Research output: Contribution to journalLetterResearchpeer-review

1 Citation (Scopus)

Abstract

[Extract] To the Editor—Venkatesan and colleagues [1] reported that outpatient neuraminidase inhibitor (NAI) treatment of influenza A(H1N1)pdm09 reduced the odds of hospitalization (unadjusted odds ratio, 0.23; 95% confidence interval [CI], .19–.28). This association, however, was driven entirely by the authors’ decision to remove patients who received NAI treatment in the community on the day of their hospital admission from their analysis. There were 1652 such patients.

Although this seems reasonable (arguing that a drug taken for no more than 1 day would be insufficient to reduce risk of hospitalization), this introduces a large bias because the dropping of these 1652 patients could not be matched for the comparison group (which, in this observational cohort study, is defined by nonreceipt of the intervention, and so no specific date can be established for nonreceipt). Restoring those 1652 patients into the analysis completely alters the direction of the effect: The crude odds ratio of hospitalization changes to 1.97 for those treated with NAIs being hospitalized compared to those who were not (Table 1).
Original languageEnglish
Number of pages1
JournalClinical Infectious Diseases
Volume65
Issue number6
Early online date13 May 2017
DOIs
Publication statusPublished - 15 Sep 2017

Fingerprint

Neuraminidase
Observational Studies
Hospitalization
Odds Ratio
Human Influenza
Cohort Studies
Research Design
Outpatients
Confidence Intervals
Therapeutics
Pharmaceutical Preparations

Cite this

@article{53f76f68e8ec486d8b26a21883889182,
title = "Findings of an observational study of neuraminidase inhibitors highly sensitive to decision to exclude 1652 treated patients",
abstract = "[Extract] To the Editor—Venkatesan and colleagues [1] reported that outpatient neuraminidase inhibitor (NAI) treatment of influenza A(H1N1)pdm09 reduced the odds of hospitalization (unadjusted odds ratio, 0.23; 95{\%} confidence interval [CI], .19–.28). This association, however, was driven entirely by the authors’ decision to remove patients who received NAI treatment in the community on the day of their hospital admission from their analysis. There were 1652 such patients.Although this seems reasonable (arguing that a drug taken for no more than 1 day would be insufficient to reduce risk of hospitalization), this introduces a large bias because the dropping of these 1652 patients could not be matched for the comparison group (which, in this observational cohort study, is defined by nonreceipt of the intervention, and so no specific date can be established for nonreceipt). Restoring those 1652 patients into the analysis completely alters the direction of the effect: The crude odds ratio of hospitalization changes to 1.97 for those treated with NAIs being hospitalized compared to those who were not (Table 1).",
author = "Mark Jones and {Del Mar}, Chris and Peter Doshi",
year = "2017",
month = "9",
day = "15",
doi = "10.1093/cid/cix425",
language = "English",
volume = "65",
journal = "Reviews of Infectious Diseases",
issn = "1058-4838",
publisher = "OXFORD UNIV PRESS INC",
number = "6",

}

Findings of an observational study of neuraminidase inhibitors highly sensitive to decision to exclude 1652 treated patients. / Jones, Mark; Del Mar, Chris; Doshi, Peter.

In: Clinical Infectious Diseases, Vol. 65, No. 6, 15.09.2017.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Findings of an observational study of neuraminidase inhibitors highly sensitive to decision to exclude 1652 treated patients

AU - Jones, Mark

AU - Del Mar, Chris

AU - Doshi, Peter

PY - 2017/9/15

Y1 - 2017/9/15

N2 - [Extract] To the Editor—Venkatesan and colleagues [1] reported that outpatient neuraminidase inhibitor (NAI) treatment of influenza A(H1N1)pdm09 reduced the odds of hospitalization (unadjusted odds ratio, 0.23; 95% confidence interval [CI], .19–.28). This association, however, was driven entirely by the authors’ decision to remove patients who received NAI treatment in the community on the day of their hospital admission from their analysis. There were 1652 such patients.Although this seems reasonable (arguing that a drug taken for no more than 1 day would be insufficient to reduce risk of hospitalization), this introduces a large bias because the dropping of these 1652 patients could not be matched for the comparison group (which, in this observational cohort study, is defined by nonreceipt of the intervention, and so no specific date can be established for nonreceipt). Restoring those 1652 patients into the analysis completely alters the direction of the effect: The crude odds ratio of hospitalization changes to 1.97 for those treated with NAIs being hospitalized compared to those who were not (Table 1).

AB - [Extract] To the Editor—Venkatesan and colleagues [1] reported that outpatient neuraminidase inhibitor (NAI) treatment of influenza A(H1N1)pdm09 reduced the odds of hospitalization (unadjusted odds ratio, 0.23; 95% confidence interval [CI], .19–.28). This association, however, was driven entirely by the authors’ decision to remove patients who received NAI treatment in the community on the day of their hospital admission from their analysis. There were 1652 such patients.Although this seems reasonable (arguing that a drug taken for no more than 1 day would be insufficient to reduce risk of hospitalization), this introduces a large bias because the dropping of these 1652 patients could not be matched for the comparison group (which, in this observational cohort study, is defined by nonreceipt of the intervention, and so no specific date can be established for nonreceipt). Restoring those 1652 patients into the analysis completely alters the direction of the effect: The crude odds ratio of hospitalization changes to 1.97 for those treated with NAIs being hospitalized compared to those who were not (Table 1).

UR - http://www.scopus.com/inward/record.url?scp=85031910891&partnerID=8YFLogxK

U2 - 10.1093/cid/cix425

DO - 10.1093/cid/cix425

M3 - Letter

VL - 65

JO - Reviews of Infectious Diseases

JF - Reviews of Infectious Diseases

SN - 1058-4838

IS - 6

ER -